Innovation in topical antifungal delivery shows promise for improved treatment of fungal infections, indicating a shift towards more effective therapies.
FFSs show superior benefits in treating superficial fungal infections by enhancing substantivity, providing sustained drug delivery, and improving adherence. Products such as single-application terbinafine films and novel nanocarrier - FFS hybrids demonstrate this potential. However, further standardized IVRT/IVPT clinical validation methods are needed to support wider adoption and ensure translation of laboratory findings into clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Rawool et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: